Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019


Here are the related meetings in 2020:
Tuberculosis: Immunity and Immune Evasion (A2)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Tuberculosis: Mechanisms, Pathogenesis and Treatment (A3)


Organizer(s) Christina L. Stallings, Veronique Anne Dartois, Stewart T. Cole and David Barros
January 17—21, 2019
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 11, 2018
Abstract Deadline: Oct 23, 2018
Scholarship Deadline: Oct 11, 2018
Discounted Registration Deadline: Nov 20, 2018

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


Summary of Meeting:
The Mycobacterium tuberculosis (TB) research and development landscape has seen many exciting breakthroughs over the past two decades. New diagnostics have emerged, innovative research has significantly reduced biological uncertainties and two novel drugs have been launched. In addition, public-private partnerships have been formed, which have dedicated massive efforts aimed at dramatically shortening TB therapy, tackling resistant disease, and developing new vaccines. However, shifts in funding priorities and a false sense of success could threaten the current focus and momentum, which would have catastrophic consequences, making the timing of this conference of paramount importance. This conference seeks to: 1) Reignite collaborative and multidisciplinary research by bringing together experts in basic science, translational research, and drug discovery and development; 2) Bring together young brilliant minds and established investigators to encourage new discussions and the exchange of innovative ideas for strategies moving forward; and 3) Foster cross-fertilization at the interface between research and development, all aspects of which are critical if we are to tackle the TB pandemic and achieve the next innovative leap.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Thursday, January 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Monday, January 21 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Tuesday, January 22 in order to fully experience the meeting.

THURSDAY, JANUARY 17

16:00—20:00
Arrival and Registration

Van Horne Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

FRIDAY, JANUARY 18

07:00—08:00
Breakfast

Van Horne B/C
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Christina L. Stallings, Washington University School of Medicine, USA

* Veronique Anne Dartois, Hackensack Meridian Health, USA

* Stewart T. Cole, Institut Pasteur, France

* David Barros, GlaxoSmithKline, Spain

Willem A. Hanekom, Bill & Melinda Gates Foundation, USA
2018: The Year of TB Vaccines!

09:00—11:45
Pathogenic Strategies of Mycobacteria
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Patricia A. Champion, University of Notre Dame, USA

Scarlet S. Shell, Worcester Polytechnic Institute, USA
The Intersection of Stress Response and RNA Metabolism in Mycobacteria

Coffee Break

Marcel A. Behr, McGill University, Canada
The Revised Time-Table of Tuberculosis and its Implications for Immunopathogenesis

Jeremy Rock, Rockefeller University, USA
Towards CRISPR-Based Functional Genomics in Mtb

Samuel H. Becker, New York University School of Medicine, USA
Short Talk: The Mycobacterium Tuberculosis Proteasome Regulates Nitrate Metabolism through an Essential Protein Quality Control System

Miriam Braunstein, University of North Carolina at Chapel Hill, USA
Short Talk: Mycobacterium tuberculosis SatS Is a Chaperone for the SecA2 Protein Export Pathway

Damian C. Ekiert, New York University School of Medicine, USA
Short Talk: MCE Protein Architectures Suggest Mechanisms of Transport Across the Envelope

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Van Horne B/C
13:00—22:00
Poster Viewing

Van Horne B/C
14:30—16:30
Workshop 1: Tuberculosis Comorbidities and Non-Tuberculosis Mycobacteria

Van Horne A
* Blanca I. Restrepo, University of Texas Health Science Center, USA

Tucker J. Piergallini, Texas Biomedical Research Institute, USA
Systemically-Increased Inflammation Causes Enhanced Early Control of Mycobacterium tuberculosis Infection in Young Mice via an Early Hyper-Inflammatory Immune Response, Mimicking M.tb Infection in Aged Mice

Anna Kathleen Coussens, Walter and Eliza Hall Institute, Australia
Seasonal Immunity in HIV-TB Pathogenesis

Brendan K. Podell, Colorado State University, USA
Early Immune Events Dictating Outcome in Diabetes-Tuberculosis Comorbidity

Ananya Nandy, CSIR-Institute of Genomics and Integrative Biology, India
Feasting on Fat: Lessons Learnt from Adipocyte Model of Mtb Infection

Julia Marianna Scordo, Texas Biomedical Research Institute, USA
Human Alveolar Lining Fluid Drives Mycobacterium tuberculosis Infection Outcome in Alveolar Epithelial Cells

Jaryd Sullivan, McGill University Health Centre, Canada
A Novel Screening Platform for Non-Tuberculous Mycobacteria Drug Discovery

Daniel Barkan, Hebrew University, Israel
The Virulence-Essential Secretion System ESX-4 in Mycobacterium abscessus Is Regulated by a Small Non-Coding RNA

Lawrence Lubyayi, University of the Witwatersrand, Uganda
Immune Sensitization and Evolution of Immune Responses Following BCG at Birth, in Infants of Mothers with and without Latent Mycobacterium tuberculosis Infection

16:30—17:00
Coffee Available

17:00—19:00
Immune Responses to Mycobacterium tuberculosis
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Anca Dorhoi, Friedrich-Loeffler-Institut, Germany

Christina L. Stallings, Washington University School of Medicine, USA
Innate Immune Responses to Mycobacterium tuberculosis

Katrin D. Mayer-Barber, NIAID, National Institutes of Health, USA
Cellular Dynamics of Innate Effector Cells during Mtb Infection

Galit Alter, Ragon Institute of MGH, MIT, and Harvard, USA
Humoral Biomarkers of Mtb Control

Jason D. Simmons, University of Washington, USA
Short Talk: Resistance to Latent Mycobacterium tuberculosis Infection Is Associated with Distinct Monocyte Transcriptional Programs

Micah Dunlap, Washington University School of Medicine, USA
Short Talk: A Novel Role for C-C Motif Chemokine Receptor 2 during Infection with Hypervirulent Mycobacterium tuberculosis

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
19:30—22:00
Poster Session 1

Van Horne B/C

SATURDAY, JANUARY 19

07:00—08:00
Breakfast

Van Horne B/C
08:00—11:15
Host Cell Signaling and Invasion
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Anna D. Tischler, University of Minnesota, USA

Jeffery S. Cox, University of California, Berkeley, USA
Using Global Proteomics to Discover New Anti-TB Pathways of Macrophages

Ulrich E. Schaible, Research Center Borstel, Germany
Pathogen-Host Cell Interactions in Tuberculosis

Coffee Break

Jyothi Rengarajan, Emory University School of Medicine, USA
Modulation of Innate-Adaptive Crosstalk in Tuberculosis

Michael Shiloh, University of Texas Southwestern Medical Center, USA
Airway Neuron Activation by Mycobacterium tuberculosis

Francisco J. Roca Soler, University of Cambridge, UK
Short Talk: TNF Induces Pathogenic Programmed Macrophage Necrosis in Tuberculosis through a Mitochondrial-Lysosomal-Endoplasmic Reticulum Circuit

Amy K. Barczak, Massachusetts General Hospital, USA
Short Talk: ER Stress and Innate Immune Recognition of Mtb Infection

Julius H. Brandenburg, Research Center Borstel, Germany
Short Talk: Mycobacterium tuberculosis Exploits WNT6-Induced Acetyl-CoA Carboxylase-2-Driven Perturbation of Host Lipid Homeostasis to Promote Growth in Macrophages

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Van Horne B/C
13:00—22:00
Poster Viewing

Van Horne B/C
14:30—16:30
Workshop 2: TB Drug Targets and MOA

Van Horne A
* Kyle H. Rohde, University of Central Florida, USA

Jyothi Padiadpu, Center for Global Infectious Disease Research, SCRI, USA
Kinome Deconvolution to Delineate Host Regulators and Inhibitors of Tuberculosis Infection

Gareth Adrian Prosser, National Institutes of Health, USA
Unraveling the Physiological Roles of the M. tuberculosis PrrAB Two-Component System

Valdir C. Barth, Rutgers University, USA
Selective Toxin-Mediated Ribosome Stalling Surgically Reprograms the Mycobacterium tuberculosis Proteome

Eachan Oliver Johnson, Broad Institute, USA
Large-Scale Chemical-Genetic Interaction Profiling Yields New Classes of Inhibitors of Mycobacterium tuberculosis

Kaley M. Wilburn, Cornell University, USA
Inducing cAMP Production in Mycobacterium tuberculosis Is Sufficient to Stall Cholesterol Utilization

Anil Kumar Ojha, Wadsworth Center, University at Albany, USA
Zincxing Mycobacterial Ribosomes: Targeting Regulation of Ribosome Hibernation to Increase Antibiotic Efficacies

Fredrik Almqvist, Umeå University, Sweden
Design, Synthesis and Evaluation of Novel ∆2- Thiazolino 2-Pyridone Derivatives as Mycobacterium Tuberculosis Tolerance Inhibitors

16:30—17:00
Coffee Available

17:00—19:00
Translation of New Therapeutic, Diagnostic and Vaccination Strategies
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Gerhard Walzl, Stellenbosch University, South Africa

Ranjan Kumar Nanda, International Center for Genetic Engineering and Biotechnology, India
Brain-Gut-Microbiota Axis in Tuberculosis

Jennifer Gardiner, Bill & Melinda Gates Foundation, USA
Biomarkers of Infection, Disease and Response to Therapy

Nicholas Paton, National University of Singapore, Singapore
New Approaches to Testing TB Regimens in Clinical Trials

Phillip A. Swanson II, National Institutes of Health, USA
Short Talk: T Cell Immunity in the Blood following Aerosol, Intravenous or Intradermal Administration of BCG in Nonhuman Primates

Brian D. Robertson, Imperial College London, UK
Short Talk: Development of a Human Challenge Model for Tuberculosis

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
19:30—22:00
Poster Session 2

Van Horne B/C

SUNDAY, JANUARY 20

07:00—08:00
Breakfast

Van Horne B/C
08:00—11:15
Treatment and Diagnosis of Disease
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Thomas Ioerger, Texas A&M University, USA

David B. Olsen, Merck and Co., USA
Intracellular Prodrug Activation Yield Selective Oxazolidinone Mycobacterium tuberculosis Inhibitors

Claudia Denkinger, Foundation for Innovative New Diagnostics, Switzerland
TB Diagnostics

Coffee Break

Rada Savic, University of California, San Francisco, USA
The Right Treatment for the Right Patient: Stratified Medicine in TB

Anthony David Baughn, University of Minnesota, USA
Conditional Susceptibility to Pyrazinamide Is Driven by a Specific Stress Response in Mycobacterium tuberculosis

Jan Rybniker, University Clinic Cologne, Germany
Short Talk: Corticosteroids Potently Abrogate p38 MAPK-Dependent Necrotic Cell Death Induced by Mycobacterium tuberculosis – Implications for Host-Directed Therapies

Janice J. Endsley, University of Texas Medical Branch, USA
Short Talk: Role of Arginine Metabolism Disruption in the Pathogenesis of TB and HIV Co-Infection

Catherine Ong, National University of Singapore, Singapore
Short Talk: MMP Inhibition Using Doxycycline with Standard Anti-Tuberculous Treatment in TB Patients: A Phase II Randomized-Controlled Trial

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Van Horne B/C
13:00—22:00
Poster Viewing

Van Horne B/C
16:30—17:00
Coffee Available

17:00—19:00
Molecular Dissection and Targeting of Mycobacterium tuberculosis
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* Bree B. Aldridge, Tufts University, USA

Robert B. Abramovitch, Michigan State University, USA
Targeting Two-Component Regulatory Systems to Inhibit Mycobacterium tuberculosis Pathogenesis

Digby F. Warner, University of Cape Town, South Africa
Catching Bacilli in Flight: Direct Sampling and Analysis of TB Aerosols

Stewart T. Cole, Institut Pasteur, France
Innovative Interventions and Imaging

Julia Puffal, Rutgers University, USA
Short Talk: Functional Compartmentalization of Plasma Membrane in Mycobacterium tuberculosis

Chiara Toniolo, Swiss Federal Institute of Technology in Lausanne, Switzerland
Short Talk: Cell-to-Cell Phenotypic Heterogeneity in the Interactions between Macrophages and Mycobacterium tuberculosis

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
19:30—22:00
Poster Session 3

Van Horne B/C

MONDAY, JANUARY 21

07:00—08:00
Breakfast

Van Horne B/C
08:00—11:15
Mycobacterial and Host Vulnerabilities
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* G. Marcela Rodriguez, University of Medicine and Dentistry of New Jersey, USA

David Barros, GlaxoSmithKline, Spain
Drug Discovery and Development in TB

Thomas Dick, Hackensack Meridian Health, USA
Mechanism of Action of PZA

Coffee Break

Mary Jackson, Colorado State University, USA
Therapeutic Potential of the FAS-II Dehydratases of Mycobacterium tuberculosis

Adrie J. C. Steyn, Africa Health Research Institute & UAB, South Africa
The Human Tuberculous Lung: An Untapped Resource to Generate a High-Resolution 3D Lung Atlas

Andrej Trauner, Swiss Tropical and Public Health Institute, Switzerland
Short Talk: Resource Misallocation as A Mediator of Fitness Costs in Rifampicin Resistance

Rujapak Sutiwisesak, University of Massachusetts Medical School, USA
Short Talk: Natural Polymorphisms in the esxH Gene of Mycobacterium tuberculosis Affect T Cell Immunity Following Infection

Daisy Xiaoxi Ji, University of California, Berkeley, USA
Short Talk: Genetic Control of the Susceptibility to M. tuberculosis Infection by the Sst1S Locus

11:15—17:00
On Own for Lunch

14:00—15:30
Careers in Science

Van Horne A
* Christina L. Stallings, Washington University School of Medicine, USA

Jeremy Rock, Rockefeller University, USA

Patricia A. Champion, University of Notre Dame, USA

Elnaz Menhaji-Klotz, Bill & Melinda Gates Medical Research Institute, USA

David Barros, GlaxoSmithKline, Spain

David B. Olsen, Merck and Co., USA

Karen Lacourciere, NIAID, National Institutes of Health, USA

15:30—16:30
Interactive Interviewing Skills

* David B. Olsen, Merck and Co., USA

16:30—17:00
Coffee Available

17:00—18:45
Host Determinants of Disease Outcomes
Meeting has ended...abstracts no longer viewable online.

Van Horne A
* David M. Tobin, Duke University School of Medicine, USA

Michael Stephen Glickman, Memorial Sloan-Kettering Institute, USA
Microbiome and Tuberculosis

Philana Ling Lin, University of Pittsburgh, USA
Nonhuman Primate Models of TB

Christopher M. Sassetti, University of Massachusetts Medical School, USA
Host and Bacterial Determinants of TB Outcome

Benjamin Henry Gern, Seattle Children's Research Institute, USA
Short Talk: TGFβ Restricts T Cell IFNɣ Production in Pulmonary Tuberculous Granulomas

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Van Horne A
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Alberta/New Brunswick

TUESDAY, JANUARY 22

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health
National Center for Advancing Translational Sciences (NCATS)

Grant No. 1 R13 AI140635-01

Funding for this conference was made possible (in part) by 1 R13 AI140635-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Merck & Co., Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179